Standout Papers
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations (2008)
- PTEN loss in the continuum of common cancers, rare syndromes and mouse models (2011)
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy (2016)
- FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia (2018)
- PTEN hamartoma tumor syndromes (2008)
Immediate Impact
8 by Nobel laureates 8 from Science/Nature 59 standout
Citing Papers
The B7:CD28 family and friends: Unraveling coinhibitory interactions
2024 Standout
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
2024 Standout
Works of Gideon M. Blumenthal being referenced
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
2021
An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Gideon M. Blumenthal | 3884 | 2494 | 1304 | 2344 | 119 | 7.2k | |
| Rajeshwari Sridhara | 4648 | 2785 | 1279 | 2952 | 137 | 9.1k | |
| Patricia Keegan | 4830 | 3055 | 1588 | 2001 | 140 | 9.0k | |
| Christophe Le Tourneau | 4735 | 2202 | 1578 | 2047 | 320 | 8.4k | |
| Alan B. Sandler | 4405 | 3602 | 1026 | 2405 | 107 | 7.4k | |
| Robert Justice | 2481 | 1657 | 856 | 2757 | 61 | 6.3k | |
| S. Percy Ivy | 3571 | 1288 | 1280 | 4056 | 187 | 7.7k | |
| William T. Barry | 4207 | 1544 | 2320 | 2111 | 189 | 8.2k | |
| Boris Freidlin | 1834 | 1291 | 1186 | 1349 | 117 | 6.2k | |
| Shenghui Tang | 2809 | 1763 | 817 | 1156 | 115 | 5.1k | |
| Shivaani Kummar | 3404 | 1447 | 1249 | 3202 | 288 | 6.8k |
All Works
Login with ORCID to disown or claim papers
Loading papers...